In this brief webinar, Niamh McGuinness, Senior CTT Analyst, will be showcasing Privacy Analytics’ new Kick-Start service offer for clinical trial data anonymization.
In this brief webinar, Niamh McGuinness, Senior CTT Analyst, will be showcasing Privacy Analytics’ new Kick-Start service offer for clinical trial document anonymization, which allows you to quickly ...
As privacy concerns continue to make headlines in the pharmaceutical space, sponsors face growing pressure to meet ever stricter regulatory requirements to anonymize clinical trial document ...
What are anonymization and de-identification? Do they mean the same thing? Is there even consensus about their meaning? Luk Arbuckle draws on his deep experience in anonymization to address these ...
Strategy development can hold you back. You want to leverage your organization’s data assets, including those containing sensitive information, but you can’t get consensus on how to…
In this session, we’ll discuss three emergent trends destined to have a major impact on your transparency planning for 2021.
As the healthcare industry evolves into an ecosystem of data-rich, digitally enabled stakeholders, drug manufacturers are losing their informational advantage in the value chain.
Once a drug company has clinical trial transparency (CTT) capabilities in place, new opportunities to drive value further along the drug development life cycle also emerge.
How effective is your organization at leveraging data across the entirety of the drug development cycle?
Extracting the value from unstructured data and addressing privacy concerns are common challenges organizations face when trying to glean insights from data.
Filter by Data Type
Categories